Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
New Leaf Pharmaceuticals LLC currently manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio has 1 pending office action, which is being handled by 1 distinct examiner. This indicates a highly focused prosecution effort, where all current activity is centered on a single application or a very small group of related filings.
The prosecution is occurring within 1 distinct art unit. COHEN, MICHAEL P is identified as the busiest examiner for the portfolio, with 1 pending office action currently under review. Because the busiest examiner pending count is 1, this individual is responsible for the entirety of the company's active office actions. This concentration means the examiner's personal interpretation of pharmaceutical patentability will be the most significant factor in the portfolio's progress.
Practitioners should focus on the specific history and preferences of this 1 distinct examiner. With only 1 pending office action in 1 distinct art unit, there are no other active cases to provide broader context or alternative paths for the portfolio. Success in the Biotechnology & Pharmaceuticals area for New Leaf Pharmaceuticals LLC requires a strategy tailored specifically to the requirements of this single examiner and the standards of their art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 1 | 58.9% | +27.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18745406 | Formulation for Nasal Delivery of Cannabinoids | COHEN, MICHAEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18745406 | Formulation for Nasal Delivery of Cannabinoids | COHEN, MICHAEL P | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18745406 | Formulation for Nasal Delivery of Cannabinoids | COHEN, MICHAEL P | 1612 | §103§112 | Final Rejection | — | Pending | Jun 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNew Leaf Pharmaceuticals LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael P Cohen has the most, with 1 of New Leaf Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
